Low‐Dose Versus High‐Dose Drug‐Coated Balloon After Jetstream Atherectomy for Severely Calcified Femoropopliteal Lesions: The JUPITER Multicenter Study
BACKGROUND: Second-generation low-dose drug-coated balloons (LD-DCBs) have shown clinical efficacy comparable to high-dose DCBs (HD-DCBs) for femoropopliteal artery (FPA) lesions. Whether paclitaxel dose density remains clinically relevant after aggressive vessel preparation with atherectomy in severely calcified FPA lesions remains uncertain. This study aimed to compare 1-year clinical outcomes of second-generation LD-DCB and HD-DCB following Jetstream atherectomy in patients with severely calcified FPA lesions. AIMS: This study aimed to compare 1-year clinical outcomes of second-generation LD-DCB and HD-DCB following Jetstream atherectomy in patients with severely calcified FPA lesions. METHODS: This multicenter retrospective study included 262 patients with severely calcified FPA lesions who underwent endovascular therapy with Jetstream atherectomy followed by second-generation LD-DCB (n = 175) or HD-DCB (n = 87). Propensity-score matching yielded 79 well-balanced pairs. The primary outcome was 1-year primary patency; secondary outcomes included freedom from clinically driven target-lesion revascularization (TLR), limb salvage, and overall survival. RESULTS: In the overall cohort before matching, 1-year primary patency was similar between second-generation LD-DCB and HD-DCB (86.8% vs. 83.1%, log-rank p = 0.578), with comparable freedom from TLR, limb salvage, and overall survival. After propensity score matching, primary patency remained similar between groups (88.5% vs. 84.9%, log-rank p = 0.588), as did freedom from TLR, limb salvage, and overall survival. Findings were consistent across calcification-related subgroups. In an exploratory Cox analysis, second-generation LD-DCB was not associated with an increased risk of restenosis compared with HD-DCB. CONCLUSIONS: After Jetstream atherectomy for severely calcified FPA lesions, second-generation LD-DCB and HD-DCB were associated with comparable 1-year clinical outcomes, suggesting that either strategy may be a reasonable treatment option.
Authors
- Kenji Ogata (ORCID: https://orcid.org/0000-0002-8563-6854)
- Kenichi Tsujita (ORCID: https://orcid.org/0000-0002-4314-259X)
- Kensaku Nishihira (ORCID: https://orcid.org/0000-0002-1718-3830)
- Takashi Yanagiuchi (ORCID: https://orcid.org/0000-0001-5179-1277)
- Takahiro Tokuda (ORCID: https://orcid.org/0000-0003-1402-062X)
- Naoki Yoshioka (ORCID: https://orcid.org/0000-0002-3619-3794)
- Tatsuya Nakama (ORCID: https://orcid.org/0000-0001-9107-6438)
- Michikazu Nakai (ORCID: https://orcid.org/0000-0003-2240-1510)
- Akiko Tanaka (ORCID: https://orcid.org/0000-0003-0238-1436)
- Tatsuro Takei (ORCID: https://orcid.org/0000-0001-8733-473X)
- Yoshisato Shibata (ORCID: https://orcid.org/0009-0000-9053-3035)
- Shunsuke Kojima (ORCID: https://orcid.org/0000-0001-7764-2165)
- Kohei Yamaguchi (ORCID: https://orcid.org/0000-0002-9336-369X)
- LEADers PAD investigators
Institutions
- Jikei University School of Medicine (JP)
- University of Miyazaki (JP)
- Rakuwakai Otowa Hospital (JP)
- Ogaki Municipal Hospital (JP)
- Nagoya Heart Center (JP)
- Sendai Kousei Hospital (JP)
- Miyazaki Medical Association Hospital (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- Catheterization and Cardiovascular Interventions
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1002/ccd.71018
- Primary Topic
- Peripheral Artery Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00